U.S. Crispr And Cas Genes Market Size & Outlook, 2024-2030
U.S. crispr and cas genes market, 2018-2030 (US$M)
Related Markets
U.S. crispr and cas genes market highlights
- The U.S. crispr and cas genes market generated a revenue of USD 1,743.9 million in 2024 and is expected to reach USD 4,145.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 15.7% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 1,743.9 million |
| Market revenue in 2030 | USD 4,145.7 million |
| Growth rate | 15.7% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.2% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 351.5 million by 2030.
Product was the largest segment with a revenue share of 87.76% in 2024. Horizon Databook has segmented the U.S. crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Other factors, such as sophisticated research & medical infrastructure, funding, skilled personnel, and companies pushing for better research methods to identify newer technologies for diagnosis & therapies, can be attributed to the significant adoption of CRISPR technology in this country.
In the U.S., CRISPR has rapidly gained popularity as a potential medical tool. In an ongoing clinical study by the University of Pennsylvania, initiated in January 2018, the first two patients had been treated using CRISPR; one patient had sarcoma and the other had multiple myeloma.
This study resulted in entry of CRISPR technology in the first human clinical trials in the U.S. Moreover, several clinical trials using CRISPR therapies are in the early stages of clinical development, especially across three treatment areas: cancer, eye disease, and blood disorders. Presence of several products in the preclinical pipeline is another factor that is expected to propel market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. crispr and cas genes market size, by product & service, 2018-2030 (US$M)
U.S. CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
